Full text is available at the source.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 25-30% of adults worldwide.
- MASLD is recognized as a systemic cardiometabolic disorder, not just a liver condition.
- Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in individuals with MASLD, surpassing liver-related deaths.
- MASLD is independently linked to atherosclerotic CVD, heart failure, and atrial arrhythmias due to mechanisms like lipotoxicity and chronic inflammation.
- Thyroid hormone receptor-β agonists improve liver health and lipid management, with cardiovascular outcomes data still pending.
- Glucagon-like peptide-1 receptor agonists may help reduce weight and improve insulin sensitivity while lowering major adverse cardiovascular events.
- Sodium-glucose cotransporter-2 inhibitors protect against heart failure and chronic kidney disease while enhancing metabolic and liver health.
Simplified